Efficacy and safety of immune checkpoint inhibitor rechallenge in non ‐small cell lung cancer: A systematic review and meta‐analysis

ConclusionsICI rechallenge is a useful therapeutic strategy for NSCLC patients, especially suitable for those who achieve long-term tumor remission for more than 2-years under 1L-ICIs.

Source: Thoracic Cancer - August 8, 2023 Category: Cancer & Oncology Authors: Yu Feng, Yunxia Tao, Haizhu Chen, Yu Zhou, Le Tang, Chenwei Liu, Xingsheng Hu, Yuankai Shi Tags: REVIEW Source Type: research